Unicancer

This study has two parts. First, it screens people with HR+ HER2-low metastatic breast cancer who are on standard CDK4/6 inhibitor therapy to find those with lingering tumor DNA in their blood—a sign of high relapse risk. Then, those high-risk patients receive the drug trastuzuma…

This trial asks whether giving a higher dose of radiation (80 Gy) is better than the standard dose (70 Gy) for men with aggressive prostate cancer who are also receiving hormone therapy. The study includes about 500 men with unfavorable prostate cancer features, such as advanced …

This phase III trial is testing whether adding the drug everolimus to standard hormone therapy can help prevent breast cancer from coming back in women with ER-positive, HER2-negative breast cancer who are at high risk of relapse. Participants have already completed at least one …

This phase 2 trial is testing whether a combination of trifluridine/tipiracil (Lonsurf) plus oxaliplatin, with or without the immunotherapy nivolumab, can help people with advanced HER2-negative stomach, esophageal, or gastroesophageal junction cancer. The study compares these co…

This phase II trial is testing whether a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and fulvestrant (a hormone blocker)—can slow or stop the growth of a specific type of advanced breast cancer. The study enrolls people with ER-positiv…

This phase 3 trial tests whether a combination of the targeted drug abemaciclib plus hormone therapy works as well as standard chemotherapy for women with ER+ HER2- breast cancer that has spread to the liver, lungs, or other organs. About 180 participants will be randomly assigne…

This study tests a drug called sacituzumab govitecan (Trodelvy) in people with advanced triple-negative breast cancer that has worsened after chemotherapy. The goal is to see how well the drug shrinks tumors and to find biological markers that predict response. Participants recei…

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This study tests whether adding focused radiation (stereotactic radiosurgery) to a combination of targeted drugs (binimetinib and encorafenib) and an immunotherapy (pembrolizumab) can better control melanoma that has spread to the brain. It includes 10 adults with a specific gene…

This study looks at whether adding surgery or radiation to a standard drug combination (palbociclib plus letrozole) can help people with newly diagnosed stage IV ER+/HER2- breast cancer live longer. About 200 women with cancer that has spread beyond the breast will receive the dr…

This study tests whether adding heated chemotherapy directly into the abdomen during surgery can help people with relapsed ovarian cancer live longer. About 415 adults whose cancer returned in the abdomen after initial treatment will take part. The approach aims to control the di…

This phase 2 trial tests whether adding mifamurtide to standard chemotherapy helps people with high-risk osteosarcoma, a type of bone cancer. The study includes 60 patients aged 2 to 50 with newly diagnosed, aggressive disease. Researchers will compare survival and relapse rates …

This phase II trial tests whether the immune-boosting drug durvalumab can help frail patients with limited-stage small cell lung cancer keep their disease from progressing after standard chemoradiotherapy. About 100 participants who have stable or improved disease after initial t…

This Phase 3 trial tests whether adding radiation to the standard combination of pembrolizumab (an immunotherapy) and chemotherapy can improve survival in people with advanced non-small cell lung cancer. About 327 participants with stage IIIB/IV disease will receive either the tr…

This study looks at whether women aged 50 and older with a very low-risk type of early breast cancer (called DCIS) can avoid radiation therapy after having breast-conserving surgery. The goal is to see if the cancer stays away without radiation, reducing unnecessary treatment and…

This study looks at whether adding a high-precision type of radiation called SBRT to usual cancer treatments (like hormone therapy or chemo) can delay cancer growth in people with breast, lung, or prostate cancer that has spread to 1 to 5 bones. About 168 adults aged 18-75 with g…

This phase 2 trial is testing whether adding the drug tucatinib to standard treatments (pertuzumab and trastuzumab) can help people with HER2-positive metastatic breast cancer whose cancer has progressed in the brain after local therapy. About 53 participants will receive tucatin…

This phase 2 trial is testing whether the immunotherapy drug atezolizumab can help control muscle-invasive bladder cancer in patients who cannot undergo bladder removal surgery. About 79 participants will receive atezolizumab after standard chemo-radiotherapy. The main goal is to…

This study is testing whether a breast cancer screening plan based on each woman's personal risk (using clinical factors and genetic markers) works better than the standard schedule. Over 53,000 women aged 40-70 are being randomly assigned to either risk-based or standard screeni…

This phase II trial tests whether riluzole, a drug used for ALS, can prevent nerve damage caused by oxaliplatin chemotherapy in people with stage II/III colorectal cancer. About 80 participants will receive either riluzole or a placebo during their chemo. The study is currently s…

This study tests whether a supervised, home-based exercise program can help people with metastatic cancer who are starting oral targeted therapy. Participants are randomly assigned to either a weekly 60-minute session with a trained coach or to a booklet with exercise recommendat…

This study is looking at how triple-negative breast cancer evolves during chemotherapy. Researchers will take biopsies from the tumor before, during, and after treatment to see if the diversity of cancer cells affects how well the tumor responds. The goal is to understand why som…

This study is investigating whether testing for a panel of 24 genes, in addition to the well-known BRCA1 and BRCA2 genes, can better estimate the risk of breast and ovarian cancer. Researchers will analyze genetic samples from people with a family history of these cancers, as wel…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can help doctors choose the right amount of chemotherapy for people with stage III colorectal cancer. About 2,450 participants will be split into groups based on their ctDNA results: those with negative c…

This study collects information from over 13,000 women treated for ovarian cancer at 18 French cancer centers. Researchers will look at patient details, tumor types, and treatments given to see how care has evolved since 2011. The goal is to understand what treatments are used an…